[go: up one dir, main page]

WO2005085285A3 - Nuclear hormone receptors - Google Patents

Nuclear hormone receptors Download PDF

Info

Publication number
WO2005085285A3
WO2005085285A3 PCT/GB2005/000801 GB2005000801W WO2005085285A3 WO 2005085285 A3 WO2005085285 A3 WO 2005085285A3 GB 2005000801 W GB2005000801 W GB 2005000801W WO 2005085285 A3 WO2005085285 A3 WO 2005085285A3
Authority
WO
WIPO (PCT)
Prior art keywords
lowbar
hormone receptors
nuclear hormone
proteins
q9bz29
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/000801
Other languages
French (fr)
Other versions
WO2005085285A2 (en
Inventor
Mark Farrow
Ian Shaw
Sarah Kamp
Lindsey Reynolds
Kirsty Leake
Janet Allen
Anna Elizabeth Lobley
Bissan Al-Lazikani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inpharmatica Ltd
Original Assignee
Inpharmatica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inpharmatica Ltd filed Critical Inpharmatica Ltd
Publication of WO2005085285A2 publication Critical patent/WO2005085285A2/en
Publication of WO2005085285A3 publication Critical patent/WO2005085285A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to certain proteins, termed, Q14185, Q92608, Q8IZD9, Q8N1I0, BAC86503, Q96HP0, Q96N67, N_212132.1, Q8NF50, XP 036307.8, Q9BZ29, Q96BY6, NP_653259.1, NP_653259.2, and mouse orthologues Q8BUR4, Q8C3J5, Q8C1Q7, P59764, Q8VDR9, Q8R1A4, Q8C147, Q8BIK4 and Q8BZN6, herein identified as containing a novel Nuclear Receptor Ligand Binding Domain and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
PCT/GB2005/000801 2004-03-04 2005-03-04 Nuclear hormone receptors Ceased WO2005085285A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0404929.2 2004-03-04
GB0404929A GB0404929D0 (en) 2004-03-04 2004-03-04 Protein

Publications (2)

Publication Number Publication Date
WO2005085285A2 WO2005085285A2 (en) 2005-09-15
WO2005085285A3 true WO2005085285A3 (en) 2006-04-27

Family

ID=32088736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/000801 Ceased WO2005085285A2 (en) 2004-03-04 2005-03-04 Nuclear hormone receptors

Country Status (2)

Country Link
GB (1) GB0404929D0 (en)
WO (1) WO2005085285A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2312354C1 (en) * 2006-07-12 2007-12-10 Государственное учреждение здравоохранения "Московский областной научно-исследовательский институт акушерства и гинекологии" Method for diagnosing estrogen- and progesteron-dependent genitalia abnormalities

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001069507A2 (en) * 2000-03-14 2001-09-20 Inpharmatica Limited Proteomics database
WO2002007557A2 (en) * 2000-07-20 2002-01-31 L-3 Communications Integrated System L.P. Substantially noiseless fastening systems for carrying packs and apparel
WO2003045321A2 (en) * 2001-11-26 2003-06-05 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2004003018A1 (en) * 2002-07-01 2004-01-08 Inpharmatica Limited Nuclear hormone receptor
WO2005016962A2 (en) * 2003-08-11 2005-02-24 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001069507A2 (en) * 2000-03-14 2001-09-20 Inpharmatica Limited Proteomics database
WO2002007557A2 (en) * 2000-07-20 2002-01-31 L-3 Communications Integrated System L.P. Substantially noiseless fastening systems for carrying packs and apparel
WO2003045321A2 (en) * 2001-11-26 2003-06-05 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2004003018A1 (en) * 2002-07-01 2004-01-08 Inpharmatica Limited Nuclear hormone receptor
WO2005016962A2 (en) * 2003-08-11 2005-02-24 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Biopendium", 19 December 2003, XP002346479 *
BOURGUET W ET AL: "Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 21, no. 10, 1 October 2000 (2000-10-01), pages 381 - 388, XP004237263, ISSN: 0165-6147 *
HASEGAWA H ET AL: "DOCK180, A MAJOR CRK-BINDING PROTEIN, ALTERS CELL MORPHOLOGY UPON TRANSLOCATION TO THE CELL MEMBRANE", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 16, no. 4, April 1996 (1996-04-01), pages 1770 - 1776, XP000985302, ISSN: 0270-7306 *
JAN C ET AL: "Sequence annotation of nuclear receptor ligand-binding domains by automated homology modeling", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 6, 2000, pages 391 - 394, XP002959343, ISSN: 0269-2139 *
LI YONG ET AL: "Activation of nuclear receptors: A perspective from structural genomics.", STRUCTURE (CAMBRIDGE), vol. 11, no. 7, July 2003 (2003-07-01), pages 741 - 746, XP002344943, ISSN: 0969-2126 *

Also Published As

Publication number Publication date
WO2005085285A2 (en) 2005-09-15
GB0404929D0 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
MX2009003093A (en) Compositions and methods relating to glucagon receptor antibodies.
EP2062917A3 (en) Antibodies to erythropoietin receptor and uses thereof
MY187263A (en) Il-17 reception a antigen binding proteins
PL1972637T3 (en) huTNFR1 selective antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
MX2007005054A (en) Vwfa and/or ant_ig domain containing proteins.
WO2004096856A3 (en) Secreted protein family
GB0300718D0 (en) Proteins
WO2006000213A3 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
WO2005085285A3 (en) Nuclear hormone receptors
WO2002070557A3 (en) Nuclear hormone receptor ligand binding domain
WO2004099782A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
GB0423126D0 (en) Protein
WO2004003010A3 (en) Nuclear hormone receptor ligano-binding domain containing protein
WO2002070561A3 (en) Nuclear hormone receptor ligand binding domain
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004009633A8 (en) Serotonin receptor
WO2004005346A3 (en) Human nuclear hormone receptor
GB0426960D0 (en) TGR-3 like protein receptor
WO2004000882A3 (en) Proteins
WO2007068913A3 (en) SRCR-B Domain Containing Proteins
WO2004003011A3 (en) Nuclear hormone receptor
ATE397755T1 (en) DIAGNOSTICS AND THERAPY METHODS OF DOPAMINE RECEPTOR D3 (DRD3) ASSOCIATED ILLNESSES
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase